Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Linperlisib by Shanghai Yingli Pharmaceutical for T-Cell Leukemia: Likelihood of Approval
Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for T-Cell Leukemia. According to GlobalData,...
Linperlisib by Shanghai Yingli Pharmaceutical for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for T-Cell Acute Lymphocytic Leukemia (T-Cell...
Linperlisib by Shanghai Yingli Pharmaceutical for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According...
Linperlisib by Shanghai Yingli Pharmaceutical for Natural Killer Cell Lymphomas: Likelihood of Approval
Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for Natural Killer Cell Lymphomas. According...